Diabetes Mellitus and the Risk of Spontaneous Bacterial Peritonitis in Patients with Liver Cirrhosis: a Systematic Review and Meta-analysis

Overview

Journal Ann Saudi Med

Specialty General Medicine

Date 2024 Aug 11

PMID 39127903

Authors

Raghad Alhajaji

Mayada Mohammad Samkari

Mona A Althobaiti

Bashaer Ruddah Al-Ahmadi

Alaa Mohammed Bugis

Amjad Mohammed Bugis

Fatimah Yaseen Sabbagh

Somaya A Althobaiti

Amro S Bukari

Safenaz Meshal Alqurashi

Hana Abdullah Mshrai

Omar Ahmed Abdelwahab

Affiliations

Soon will be listed here.

Abstract

Background: Spontaneous bacterial peritonitis (SBP) represents a critical and potentially lethal condition that typically develops in individuals with liver cirrhosis. This meta-analysis aimed to assess diabetes mellitus (DM) as a risk factor for SBP in liver cirrhotic patients.

Methods: Following PRISMA guidelines, fifteen studies were included, for a total of 76 815 patients. The risk of bias was assessed using the Newcastle-Ottawa scale (NOS). We represented the results as risk ratios (RR) with the corresponding 95% confidence intervals (CI) using RevMan software. Additionally, we pooled the hazard ratios (HR) for developing SBP in patients with DM from the included studies.

Results: The meta-analysis shows a significantly increased risk of SBP in cirrhotic patients with DM (HR: 1.26; 95% CI [1.05-1.51], =.01; HR: 1.70; 95% CI [1.32-2.18], <.001).

Conclusions: The study signifies that DM is an independent risk factor for SBP, emphasizing the need for targeted preventive measures in this specific population.

References

Rohm T, Meier D, Olefsky J, Donath M . Inflammation in obesity, diabetes, and related disorders. Immunity. 2022; 55(1):31-55. PMC: 8773457. DOI: 10.1016/j.immuni.2021.12.013. View

Wlazlo N, Van Greevenbroek M, Curvers J, Schoon E, Friederich P, Twisk J . Diabetes mellitus at the time of diagnosis of cirrhosis is associated with higher incidence of spontaneous bacterial peritonitis, but not with increased mortality. Clin Sci (Lond). 2013; 125(7):341-8. DOI: 10.1042/CS20120596. View

Nusrat S, Khan M, Fazili J, Madhoun M . Cirrhosis and its complications: evidence based treatment. World J Gastroenterol. 2014; 20(18):5442-60. PMC: 4017060. DOI: 10.3748/wjg.v20.i18.5442. View

Kosmalski M, Ziolkowska S, Czarny P, Szemraj J, Pietras T . The Coexistence of Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus. J Clin Med. 2022; 11(5). PMC: 8910939. DOI: 10.3390/jcm11051375. View

Sigal S, Stanca C, Kontorinis N, Bodian C, Ryan E . Diabetes mellitus is associated with hepatic encephalopathy in patients with HCV cirrhosis. Am J Gastroenterol. 2006; 101(7):1490-6. DOI: 10.1111/j.1572-0241.2006.00649.x. View

Skinner C, Thompson A, Thursz M, Marchesi J, Vergis N . Intestinal permeability and bacterial translocation in patients with liver disease, focusing on alcoholic aetiology: methods of assessment and therapeutic intervention. Therap Adv Gastroenterol. 2020; 13:1756284820942616. PMC: 7580143. DOI: 10.1177/1756284820942616. View

Arvanitakis K, Koufakis T, Kalopitas G, Papadakos S, Kotsa K, Germanidis G . Management of type 2 diabetes in patients with compensated liver cirrhosis: Short of evidence, plenty of potential. Diabetes Metab Syndr. 2024; 18(1):102935. DOI: 10.1016/j.dsx.2023.102935. View

Garcia-Compean D, Jaquez-Quintana J, Gonzalez-Gonzalez J, Maldonado-Garza H . Liver cirrhosis and diabetes: risk factors, pathophysiology, clinical implications and management. World J Gastroenterol. 2009; 15(3):280-8. PMC: 2653324. DOI: 10.3748/wjg.15.280. View

Aithal G, Palaniyappan N, China L, Harmala S, Macken L, Ryan J . Guidelines on the management of ascites in cirrhosis. Gut. 2020; 70(1):9-29. PMC: 7788190. DOI: 10.1136/gutjnl-2020-321790. View

10.

Huang D, Terrault N, Tacke F, Gluud L, Arrese M, Bugianesi E . Global epidemiology of cirrhosis - aetiology, trends and predictions. Nat Rev Gastroenterol Hepatol. 2023; 20(6):388-398. PMC: 10043867. DOI: 10.1038/s41575-023-00759-2. View

11.

Neff G, Kemmer N, Duncan C, Alsina A . Update on the management of cirrhosis - focus on cost-effective preventative strategies. Clinicoecon Outcomes Res. 2013; 5:143-52. PMC: 3632499. DOI: 10.2147/CEOR.S30675. View

12.

Campbell M, Obstein K, Reddy K, Yang Y . Association between proton pump inhibitor use and spontaneous bacterial peritonitis. Dig Dis Sci. 2007; 53(2):394-8. DOI: 10.1007/s10620-007-9899-9. View

13.

Singh M, Das B, Choudhary S, Gupta D, Patil U . Diabetes and hepatocellular carcinoma: A pathophysiological link and pharmacological management. Biomed Pharmacother. 2018; 106:991-1002. DOI: 10.1016/j.biopha.2018.06.095. View

14.

Liu Z, Yan Y, Weng H, Ding H . Type 2 diabetes mellitus increases liver transplant-free mortality in patients with cirrhosis: A systematic review and meta-analysis. World J Clin Cases. 2021; 9(20):5514-5525. PMC: 8281398. DOI: 10.12998/wjcc.v9.i20.5514. View

15.

Kraja B, Sina M, Mone I, Pupuleku F, Babameto A, Prifti S . Predictive Value of the Model of End-Stage Liver Disease in Cirrhotic Patients with and without Spontaneous Bacterial Peritonitis. Gastroenterol Res Pract. 2012; 2012:539059. PMC: 3296141. DOI: 10.1155/2012/539059. View

16.

Mattos A, Wiltgen D, Jotz R, Dornelles C, Fernandes M, Mattos A . Spontaneous bacterial peritonitis and extraperitoneal infections in patients with cirrhosis. Ann Hepatol. 2020; 19(5):451-457. DOI: 10.1016/j.aohep.2020.04.010. View

17.

Lee S, Saffo S . Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy. World J Gastroenterol. 2023; 29(1):61-74. PMC: 9850948. DOI: 10.3748/wjg.v29.i1.61. View

18.

Chavez-Reyes J, Escarcega-Gonzalez C, Chavira-Suarez E, Leon-Buitimea A, Vazquez-Leon P, Morones-Ramirez J . Susceptibility for Some Infectious Diseases in Patients With Diabetes: The Key Role of Glycemia. Front Public Health. 2021; 9:559595. PMC: 7921169. DOI: 10.3389/fpubh.2021.559595. View

19.

Begg C, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4):1088-101. View

20.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View